January FDA update

Management noted that the revised FDA application to approve phase 3 trials will be lodged end Nov/early December so weeks away, for those that care have a look at PAR (Paradigm) share price and multiple similarities to MVP in that the drug has been around for ages.

PAR got the tick of approval today and is up circa 20%.

At the AGM MVP said we get an outcome from the FDA in January and best case the phase 3 trial will begin mid 2022, they seemed upbeat and confident this will get the tick to approve the trial.

So point being thats a hugely price sensitive moment on the horizon plus China study starts on humans before Christmas and a Canadian distributor announced any day now.

Plenty to like on top of huge revenue lift from Europe, i'm full to the gills but my gut says buy more........